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Abstract
Background Patients diagnosed with primary central nervous system lymphoma (PCNSL) often face dismal outcomes due to 
the limited availability of therapeutic options. PCNSL cells frequently have deregulated B-cell receptor (BCR) signaling, but 
clinical responses to its inhibition using ibrutinib have been brief. In this regard, blocking nuclear export by using selinexor, 
which covalently binds to XPO1, can also inhibit BCR signaling. Selinexor crosses the blood–brain barrier and was recently 
shown to have clinical activity in a patient with refractory diffuse large B-cell lymphoma in the CNS. We studied selinexor 
alone or in combination with ibrutinib in pre-clinical mouse models of PCNSL.
Methods Orthotopic xenograft models were established by injecting lymphoma cells into the brain parenchyma of athymic 
mice. Tumor growth was monitored by bioluminescence. Malignant cells and macrophages were studied by immunohisto-
chemistry and flow cytometry.
Results Selinexor blocked tumor growth and prolonged survival in a bioluminescent mouse model, while its combination 
with ibrutinib further increased survival. CNS lymphoma in mice was infiltrated by tumor-promoting M2-like macrophages 
expressing PD-1 and SIRPα. Interestingly, treatment with selinexor and ibrutinib favored an anti-tumoral immune response 
by shifting polarization toward inflammatory M1-like and diminishing PD-1 and SIRPα expression in the remaining tumor-
promoting M2-like macrophages.
Conclusions These data highlight the pathogenic role of the innate immune microenvironment in PCNSL and provide pre-
clinical evidence for the development of selinexor and ibrutinib as a new promising therapeutic option with cytotoxic and 
immunomodulatory potential.
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COO  Cell of origin
CLL  Chronic lymphocytic leukemia
TAM  Tumor-associated macrophages
M-CSF  Macrophage colony-stimulating factor
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Background
Primary central nervous system lymphoma (PCNSL) is a 
rare and aggressive non-Hodgkin lymphoma (NHL) local-
ized to the CNS in the absence of systemic involvement 
that represents around 4% of all brain tumors and 4 to 
6% of all extranodal lymphomas [1]. Approximately 95% 
of PCNSL are classified as activated B-cell diffuse large 
B-cell lymphoma (ABC-DLBCL) based on histopathol-
ogy, gene expression and mutational landscape [2]. Cur-
rent treatment options for PCNSL include high doses of 
chemotherapy able to cross the blood–brain barrier (BBB) 
combined with anti-CD20 monoclonal antibodies and the 
addition of whole brain radiation in some settings; also, 
autologous stem cell transplantation is considered for young 
patients. Patients diagnosed with PCNSL respond poorly to 
the available treatments and often face dismal outcomes, 
especially in the relapsed setting, with an estimated over-
all survival of 30% at 5 years [3]. This notion of the poor 
prognosis of PCNSL can be explained by particular biologi-
cal characteristics of the tumor. First, PCNSL are charac-
terized by a high frequency of concomitant MYD88 and 
CD79B mutations [4] along with lesions related to B-cell 
development and function (e.g. BLIMP1), and the NF-κB 
pathway (e.g. CARD11 or TBL1XR1). The involvement of 
the BCR signaling in PCNSL has prompted the use of the 
BTK inhibitor ibrutinib, that, although it can cross the BBB 
[5], achieves wide but short duration responses [6–8]. In 
addition, PCNSL develop in a special microenvironment 
of unique immune surveillance, which could contribute to 
an inefficient response of the immune system against lym-
phoma cells. In this regard, the few reports examining the 
tumor-infiltrating immune microenvironment show that it is 
mainly composed by macrophages and by T-cells to a lesser 
extent [9–13]. Also, an intriguing high proportion of PCNSL 
have genetic lesions that potentially avoid being recognized 
by T-cells, namely HLA loses and PD-L1/2 amplifications 
found in up to 80% of patients [14]. Finally, the poor prog-
nosis can also be explained by the diminished capacity of 
some drugs to cross the BBB. Selinexor (KPT-330), a BBB 
permeable small molecule [15], is a Selective Inhibitor of 
Nuclear Export (SINE) compound that binds to the cargo 
binding pocket of XPO1 (exportin-1/CRM1) and inhibits its 
activity. This results in the nuclear accumulation of tumor 
suppressor proteins and cell cycle regulators together with 
the activation of tumor suppressor proteins, which translates 
in cell cycle arrest and specific anti-cancer activity across 
a wide range of hematological and solid malignancies [16]. 
In July 2019, selinexor was approved by the FDA to treat 
patients with multiple myeloma while in May 2020 it was 
approved for systemic relapsed/refractory DLBCL after 
positive results in a phase IIb trial [17]. Also, the ability of 
selinexor to inhibit both the BCR and the NF-κB signaling 
pathways makes this drug interesting for studies in NHL [16, 
18]. Recently, in a clinical case study, selinexor was reported 
to inhibit refractory DLBCL with CNS involvement [19]. In 
order to provide a pre-clinical rationale for the design of new 
therapeutic strategies for patients diagnosed with PCNSL, 
herein we evaluate the role of XPO1 and BTK inhibition in 
intracerebral xenograft murine models, focusing on malig-
nant cells and the innate immune microenvironment.
Materials and methods
In vivo modeling of PCNSL
All animal experiments were approved by the local Ethical 
Committee for the Use of Experimental Animals. Detailed 
methods including treatment schedules can be found in Sup-
plementary information. Briefly, brains of eight-week-old 
athymic female mice were injected with OCI-Ly10 cells sta-
bly transfected with luciferase, as previously reported [20]. 
Tumor growth was monitored by bioluminescence imaging 
(BLI) using IVIS® Spectrum system and Living Image soft-
ware (PerkinElmer).
Patient derived xenograft (PDX) model was established 
by intracerebral injection of human lymphoma cells iso-
lated from a brain biopsy in eight-week-old NOD-SCID-γ 
(NSG) female mice. Next, expanded  CD19+ tumor cells 
were inoculated into the brain parenchyma of eight-week-
old athymic female mice as specified above. Human tumor 
sample was obtained from a patient diagnosed with PCNSL 
at Hospital Universitari Joan XIII, Tarragona (Spain) after 
approval from the local Clinical Research Ethics Committee 
according to the principles of the Declaration of Helsinki 
and obtaining written informed consent from the patient.
Flow cytometry and immunohistochemistry (IHC) 
analysis
Mice brains were collected in cold RPMI-1640 medium 
immediately after euthanasia and the two hemispheres were 
separated with a razor blade. One hemisphere was used 
for IHC and the other one was processed for flow cytom-
etry. Detailed methods can be found in Supplementary 
information.
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Statistical analysis
Results are expressed as the mean ± standard error of the 
mean (SEM) of at least four independent experiments or 
subjects. The statistically significant differences between 
groups were analyzed using the Mann–Whitney test or 
one or two-way ANOVA, and P < 0.05 was considered sig-
nificant. Detailed methods can be found in Supplementary 
information.
Results
DLBCL cell lines have equivalent sensitivity 
to selinexor regardless of their cell of origin (COO)
ABC-DLBCL relies heavily on NF-κB signaling and shows 
chronic BCR activation that is needed for survival, which 
translates into differential sensitivity to drugs targeting 
these pathways between ABC and GCB DLBCL cases [21, 
22]. Since increased expression of XPO1 has been related 
to resistance to chemotherapy and worse prognosis in dif-
ferent neoplasias [23], we studied the potential relationship 
between expression of XPO1 and sensitivity to selinexor in 
DLBCL cell lines. Although mRNA expression of XPO1 
was significantly higher in ABC-DLBCL cell lines (Fig. 1a), 
we did not find differential in vitro sensitivity to selinexor 
according to COO (Fig. 1b, c). Finally, we interrogated 
the publicly available data on gene expression of primary 
DLBCL cases [24] and we did not observe any association 
between the COO and the expression of XPO1 (Fig. 1d).
Selinexor blocks tumor growth and prolongs 
survival in a bioluminescent orthotopic mouse 
model of PCNSL.
We next assessed the role of XPO1 inhibition in PCNSL 
using an intracerebral orthotopic xenograft murine model 
established by stereotactic injection of the luciferase-
expressing OCI-Ly10 cell line into the cerebral parenchyma 
of nude athymic mice. OCI-Ly10 cell line was selected 
because it is derived from a patient diagnosed with ABC-
DLBCL and its genetic profile includes mutations in MYD88 
(L265P) and CD79A (c. 4275_4316del) genes [20] (further 
verified in house), frequent in PCNSL [4]. Additionally, 
OCI-Ly10 cells have successfully been used before in a 
PCNSL xenograft model in athymic mice for pre-clinical 
studies [20]. Tumoral growth was monitored using IVIS-
Spectrum bioluminescence measurement. Eleven days after 
the injection of cells, all animals had developed detectable 
tumors restricted to the CNS and were randomly distributed 
into treatment or vehicle experimental groups (vehicle: n = 8, 
mean radiance = 1.16·107 ph/s ± 0.615·107; treatment: n = 9, 
mean radiance = 2.32·107 ph/s ± 1.86·107). Mice were dosed 
with 5 mg/kg of selinexor or vehicle via oral gavage three 
times a week and subsequently, in order to non-invasively 
monitor the tumor growth, bioluminescence was assessed 
twice a week (Fig. 1e). Dose was selected based on previous 
pre-clinical data in mouse models of different neoplasias 
[25]. Treated mice showed a significantly slower increase 
in bioluminescence signal along time (two-way ANOVA: 
p = 0.0002; Fig.  1f) indicating that the treatment with 
selinexor was able to notably slow down tumor growth. Spe-
cific time-point analysis showed that differences were signif-
icant as soon as 12 days after start of treatment (day 23 after 
injection: vehicle mean radiance 2.61·108 ph/s ± 8.64·107 
vs. 3.73·107 ph/s ± 1.9·107 in selinexor; p = 0.011) while 
differences peaked at day 20 after treatment (day 31 after 
injection: 8.98·108 ph/s ± 3.13·108 in vehicle vs. 1.19·108 
ph/s ± 5.58·107 in selinexor group; p = 0.0037; Fig. 1f, rep-
resentative cases can be seen in Fig. 1h). The blockage of 
intracerebral lymphoma growth induced by selinexor trans-
lated into a significantly increased survival, with a median 
survival of 48 days in the treatment group compared to 
34 days in the vehicle group (p < 0.0001; Fig. 1g). At final 
point, histopathological analysis showed multifocal and infil-
trative tumors affecting cerebral parenchyma and meninges 
of both cerebral hemispheres. Cells were highly prolifera-
tive (Ki-67 100%), CD20-positive and were often found in 
the perivascular space resembling human PCNSL histology. 
Remarkably, infiltration was observed in both hemispheres, 
showing no preference for the right hemisphere, where the 
original inoculation of malignant cells was performed. Also, 
we did not observe variations in CD20 intensity among mice 
or within different areas of the same brain (representative 
cases shown at Fig. 1i and Supplemental Figure S1).
The combination of selinexor and ibrutinib 
synergizes in vitro in DLBCL cell lines and increases 
survival of mice with CNS lymphoma
The high frequency of molecular alterations in compo-
nents of the BCR pathway can in part explain the response 
to BCR inhibitors in PCNSL. In this regard, ibrutinib in 
monotherapy in patients diagnosed with relapsed or refrac-
tory PCNSL achieves higher response rates compared to 
systemic DLBCL, however, the duration of the response 
is brief [5–7]. Alongside this, SINE compounds have also 
been shown to inhibit BCR signaling by downregulating the 
protein expression of BTK via enforced IκB nuclear reten-
tion in primary cells from patients with chronic lympho-
cytic leukemia (CLL) [16]. Moreover, the combination of 
selinexor and ibrutinib has shown in vitro synergism in CLL 
cells [18]. Accordingly, we observed reduced BCR signaling 
after treatment of OCI-Ly10 cells with selinexor and ibru-
tinib (Supplementary Figure S2A), as well as reduced BTK 
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expression after 48 h of treatment with selinexor (Supple-
mentary Figure S2B). Against this background, we hypoth-
esized that combining XPO1 and BTK inhibition in PCNSL 
would have a synergistic therapeutic effect in our models. 
Firstly we treated a panel of cell lines in vitro with increas-
ing doses of both drugs and analyzed apoptosis after 96 h. 
In three out of four ABC-DLBCL cell lines we observed 
a strong synergism between the two compounds (Supple-
mentary Figure S2C); remarkably, treatment with selinexor 
sensitized GCB-SUDHL4 cells to ibrutinib, as shown by 
the combination index values indicating strong synergism 
between the two drugs (CI) (Supplementary Figure S2C, 
right panel).
We next sought to elucidate whether the synergy observed 
in vitro could be translated in vivo. Importantly, while 
ibrutinib is mainly metabolized by cytochrome P450, the 
metabolism of selinexor is independent of it, therefore it 
is unlikely that their co-administration could result in any 
effects on the exposure for the other drug [25, 26]. By using 
the same animal model described above, mice were dis-
tributed into the following four groups and started therapy 
11 days after intracerebral injection of lymphoma cells: 
ABC
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Fig. 1  In vitro and in vivo effects of selinexor in PCNSL models. a 
XPO1 relative expression by QRT-PCR. Cells were treated with 
increasing doses of selinexor or vehicle (1% DMSO) for 96  h and 
viability and proliferation was determined by Annexin-V-PI exclu-
sion (b) or MTS method (c). d Relative XPO1 expression in DLBCL 
patients, using public data from ref [24]. e Scheme representing mice 
treatment and monitoring. f Tumor size as measured by BLI in mice 
treated with vehicle (n = 8) or selinexor (n = 9). Data is shown until 
day 31, last day when all animals were still alive. Two-way ANOVA 
analysis (P = 0.0002). Asterisks indicate the result of Mann–Whitney 
test at different time points. (*P < 0.05, **P < 0.01, ***P < 0.001. 
Graphs show mean ± SEM) (g) Survival curves and (h) representa-
tive BLI images of the CNS tumors. i IHC analysis showing expres-
sion of CD20 and Ki-67 in representative mice brain parenchyma and 
meninges. The bars represent 5 mm in top panels and 250 µm in bot-
tom panels. ID50: inhibitory dose 50. ABC: activated-B cell. GCB: 
germinal center B-cell. BLI: bioluminescence imaging. Ph/s: photons 
per second. (*P < 0.05, **P < 0.01, Mann–Whitney test. Graphs show 
mean ± SEM)
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selinexor monotherapy (5 mg/kg twice a week via oral gav-
age, n = 12, mean radiance = 3.95·106 ph/s), ibrutinib mono-
therapy (25 mg/kg daily in drinking water, n = 9, mean radi-
ance = 1.02·107 ph/s), combination therapy (n = 11, mean 
radiance = 1.02·107 ph/s) and vehicle (n = 9, mean radi-
ance = 3.21·106 ph/s). Selinexor dose was adjusted (from 
three times a week to twice a week) in order to prevent 
potential toxicity of the drug combination, while ibrutinib 
dose was based on previous experience in CLL preclinical 
models [27] (Fig. 2a). Compared to vehicle, all three treat-
ment regimens induced an equivalent significant effect in 
tumor growth kinetics in terms of decreased growth rate 
(Fig. 2b and c). Interestingly, the combination increased the 
survival of mice compared to vehicle, whereas there was 
no significant difference between ibrutinib and selinexor 
alone. Although the median survival increased up to 55 days, 
the survival curve of the mice treated with the combina-
tion was not statistically different from the ones from mice 
treated with the individual treatments (median survival of 
mice treated with vehicle: 35 days vs. survival for mice 
treated with selinexor: 40 days, p = 0.001; vehicle vs. ibru-
tinib, 43 days, p = 0.0005; vehicle vs. combination, 55 days, 
p = 0.0001; Fig. 2d).
CNS lymphoma is infiltrated by tumor‑promoting 
M2‑like macrophages expressing PD‑1 and SIRPα
Analysis of the tumor-infiltrating immune microenviron-
ment has shown that tumoral cells in PCNSL are accom-
panied by tumor-associated macrophages (TAMs) and 
T-cells to less extend, which is related to bad prognosis. 
[9–13] Remarkably, TAMs in mouse and human colo-
rectal cancer have been recently described to express the 
immune checkpoint PD-1 and to recover their potential 
to phagocyte tumoral cells when PD-1 is blocked [28]. 
To conduct an interactive study of the infiltrating innate 
immune cells and PCNSL, we inoculated OCI-Ly10 cells 
into the brain parenchyma of nude athymic mice, an exper-
imental in vivo model that has been previously success-
fully used to study the modulation of the innate immune 
response against PCNSL [20, 29]. Brains were harvested 
after 24 days of cell injection and further processed for 
subsequent analysis. Histopathological analysis showed 
that tumors encompassing both cerebral hemispheres were 
infiltrated by macrophages expressing the surface glyco-
protein F4/80, mainly in the meninges but also in the cer-
ebral parenchyma; notably, F4/80-positive macrophages 
Fig. 2  Treatment with selinexor and ibrutinib further increases sur-
vival of mice with CNS lymphoma. a Scheme representing mice 
treatment and monitoring. b Tumor size as measured by BLI inten-
sity. Data is shown until day 29, last day when all animals were still 
alive. (*P < 0.05, **P < 0.01, ***P < 0.001, Mann–Whitney test. 
Graphs show mean ± SEM). c Representative BLI images in mice 
from every treatment arm. d Survival curves of mice in the four treat-
ment groups. Survival curves were generated using the Kaplan and 
Meier method, and statistically compared by the log-rank test. HR 
hazard ratio, CI confidence interval, BLI bioluminescence imaging
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were completely absent in the areas of the brain that were 
not invaded by tumoral cells (Figs. 3a and Supplemen-
tal figure S1) as well as in healthy brains from control 
mice (Fig. 3a). Iba-1 staining further identified microglial 
cells and TAMs, which showed an amoeboid morphol-
ogy when interacting with tumoral cells, consistent with 
an active state (Fig. 3a) [30]. TAMs can be polarized 
towards a pro-inflammatory (M1) or a tumor-promoting 
(M2) state, depending on microenvironment and external 
stimuli [31]. By flow cytometry, we analyzed the propor-
tion of M1 and M2 TAMs and their expression of immune 
checkpoints in brains from mice with PCNSL. First, we 
observed that TAMs were evenly distributed between M1 
and M2 (Fig. 3c). Of note, TAMs expressed PD-1, mainly 
the tumor promoting M2 subset (Fig. 3d). This suggests 
that the direct interaction of M2 macrophages with the 
tumor triggers the upregulation of PD-1 and thus impairs 
their phagocytic capacity, as has been recently discovered 
in an analogous role to tumor-infiltrating T-cells using 
both immunocompetent syngeneic and athymic xenograft 
mouse models [28]. SIRPα is a well described regulatory 
checkpoint on macrophages, its interaction with CD47 
on malignant cells hampering the phagocytosis by mac-
rophages [32]. Herein we observed that SIRPα was also 
preferentially expressed by M2 TAMs (Fig. 3e) and that 
the co-expression of PD-1 and SIRPα was also higher in 
the M2 subset (Fig. 3f), pointing out towards a severe inhi-
bition of macrophage activity in CNSL.
The response of the innate immune system to PCNSL 
cells derived from a patient was further analyzed. For that, 
we developed an orthotopic PDX model using NSG mice 
to initially expand the freshly obtained primary malig-
nant cells, as previously described by Rubenstein et al. and 
following the detailed protocol described in Supplemen-
tary methods [33] Next, we inoculated 2·105 lymphoma 
cells into the brain parenchyma of nude athymic mice 
[34]. Since the median survival of this mouse model was 
22 days, infiltration by immune cells was analyzed after 
18 days of tumor injection allowing infiltration by innate 
immune cells. In this model, TAMs were also found only 
amongst tumoral cells (Figs. 4a and Supplemental Figure 
S3) as assessed by IHC. TAMs from the PDX model dis-
played an immunophenotypic profile resembling the one 
found in TAMs from the cell line xenograft model. Along 
this line, a similar proportion of M1 and M2 (Fig. 4b) 
and a more frequent expression of PD-1 and SIRPα in 
M2 tumor-promoting macrophages was observed (Fig. 4c, 
d, e). In contrast to the OCI-Ly10 model, patient-derived 
PCNSL cells did express the SIRPα ligand CD47 (97.61% 
of CD20 cells ± 0.62).
Fig. 3  OCI-Ly10 CNS lymphomas are infiltrated by innate immune 
cells. a Representative IHC images from brains obtained from three 
mice inoculated with OCI-Ly10 cells (24  days after injection). The 
bar represents 500 µm, except for fourth and last rows (50 µm). b Gat-
ing strategy for the analysis of TAMs. Percentage of macrophages 
(M1/M2) (c) expressing PD-1 (d), SIRPα (e) and co-expressing both 
(f)
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Treatment with selinexor and ibrutinib favors 
TAM polarization toward pro‑inflammatory 
M1‑like and diminishes PD‑1 and SIRPα expression 
in M2‑like TAMs
BTK protein has been shown to be crucial for tumor-promot-
ing function of macrophages in different neoplasias, espe-
cially in CLL, where modulation of TAMs has been shown 
to be also a relevant mode of action of ibrutinib [35, 36]. 
Therefore, after showing that the combination of selinexor 
and ibrutinib restrains tumor growth and prolongs mice 
survival, and since both drugs are able to inhibit BTK, we 
hypothesized that these drugs could also cooperate to mod-
ify the innate immune response in PCNSL. In this regard, 
pre-clinical PCNSL models have previously demonstrated 
how immunomodulating drugs are able to shift macrophages 
polarization as well as have direct antitumoral effect. [20, 
29] To test that, we treated mice bearing OCI-Ly10-CNS 
lymphomas with selinexor 5 mg/kg twice a week, ibrutinib 
25 mg/kg daily or the combination of the two drugs for two 
weeks by oral gavage (Fig. 5a). We observed that selinexor 
and the combination shifted the M1/M2 ratio towards pre-
dominance of anti-tumoral M1 (Fig.  5b). Interestingly, 
while none of the individual treatments induced significant 
changes in the frequency of PD-1 or SIRPα-positive M2 
macrophages, the drug combination significantly reduced 
the frequency of PD-1-positive, SIRPα-positive (Fig. 5c, d, 
e) and double-positive M2 macrophages (Fig. 5f). In agree-
ment the (CI) that the reduction of the expression of PD-1, 
SIRPα and their co-expression was synergistic (CI < 1). This 
was accompanied by a reduction in PD-L1-expressing malig-
nant cells (Fig. 5g, h) that was attributable to ibrutinib action 
since it was also observed under ibrutinib monotherapy.
In the PDX model, the study of immunomodulation was 
performed 18 days after cell injection preceded by 12 days 
of oral gavage treatment as described earlier (Fig. 6a). 
Both treatments alone or in combination were able to 
change the M1/M2 balance towards a more anti-tumoral 
or inflammatory response (Fig. 6b). Moreover, treatment 
with ibrutinib only or with the drug combination was 
able to diminish the frequency of PD-1-positive M2 mac-
rophages (Fig. 6c). The frequency of SIRPα-positive M2 
macrophages was also diminished by both individual treat-
ments, as well as the double positive M2 cells (Fig. 6d and 
e). In this mouse model we did not observe any effect in 
the expression of PD-L1 by the malignant cells, while the 
percentage of malignant cells was also not affected by the 
short term treatment (Fig. 6f and g). Expression of CD47 
by patient-derived PCNSL cells was significantly down-
regulated after treatment with the combination (Fig. 6h). 
Fig. 4  PDX CNS lymphomas are infiltrated by innate immune cells. 
a Representative IHC images from brains obtained from two  mice 
inoculated with patient-derived PCNSL cells (18 days after injection). 
The bar represents 100 µm except for the four last rows (50 µm). Per-
centage of macrophages (M1/M2) (b) expressing PD-1 (c), SIRPα 
(d) and co-expressing both (e). (*P < 0.05, **P < 0.01, ***P < 0.001, 
Mann–Whitney test. Graphs show mean ± SEM)
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Accordingly, CI calculations show that the combination 
did not improve upon individual treatments for any of the 
parameters except for the expression of CD47 on malig-
nant cells. In order to identify direct immunomodulatory 
effects of selinexor and ibrutinib on human macrophages, 
we treated peripheral blood-derived macrophages in vitro 
with increasing doses of selinexor, ibrutinib or the com-
bination for 30 min before inducing differentiation to M2 
using macrophage colony-stimulating factor (M-CSF) 
and IL-10 (see Supplementary information for detailed 
methods). M2 macrophages derived from 8 healthy donors 
had a mean expression of PD-1 of 81.15% + /−8.8 and 
mean expression of SIRPα of 45.53% + /−9.3. Firstly, we 
made sure that the drugs did not affect survival of mac-
rophages at the concentrations used (data not shown). 
Next, in agreement with what we observed in vivo, we 
observed downregulation of the expression of both PD-1 
and SIRPα caused by individual drugs or the combination. 
(Supplementary Figures S4A, S4B and S4C). However, 
Fig. 5  Treatment with selinexor and ibrutinib favors M1-like 
response in tumor-associated macrophages in OCI-Ly10-derived CNS 
lymphomas. a Scheme representing mice treatment and monitoring. 
b Percentage of M1 and M2 TAMs by flow cytometry. c Histograms 
of  PD1+ M2 and SIRPα+ M2 of one representative mouse from each 
group. Frequency of M2 macrophages that express PD-1 (d), SIRPα 
(e) or co-express both markers (f). g Percentage of  CD20+ cells in 
the brains from mice treated for two weeks. h Percentage of  CD20+ 
malignant cells expressing PD-L1 in the different treatment groups. 
(*P < 0.05, **P < 0.01, ***P < 0.001, Mann–Whitney test. Graphs 
show mean ± SEM). CI combination index, BLI bioluminescence 
imaging
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this did not translate into increased phagocytic activity 
(Supplementary Figure S4D).
Also, using the same experimental setting we analyzed 
the effect of selinexor, ibrutinib or the combination  in 
interfering with M2 polarization by analyzing additional 
M1 and M2-like markers and IL-10 production. We found 
an increase in the expression of the activation and M1-like 
marker CD86 and a decrease in the M2-like marker CD163 
as well as lower levels of PD-L1 and the anti-inflammatory 
cytokine IL-10 after treatment with selinexor and ibrutinib 
(Supplementary Figures S4E-H). However, we did not see 
any significant effect in the expression of CD206 or HLA-
DR (Supplementary Figures S4I–J). In vitro modulation 
of additional surface markers and cytokines is consistent 
with the loss of pro-tumoral M2 properties after treatment 
with selinexor and ibrutinib.
Altogether these results indicate that the combination 
of selinexor and ibrutinib is able to block tumoral growth, 
to significantly increase the median survival of mice with 
PCNSL and to modulate the innate immune microenviron-
ment towards a more anti-tumoral stage, likely reinvigor-
ating the anti-tumoral phagocytic function of the tumor 
infiltrating macrophage population in vivo.
Discussion
Blockage of XPO1-mediated nuclear transport using 
SINEs like selinexor has been shown to be an effective 
anti-neoplastic approach in a variety of malignancies. 
[17, 37, 38] XPO1 inhibition forces nuclear localization 
of tumor suppressors and also interferes with additional 
signaling pathways, including NF-κB and BCR, which are 
crucial for survival of malignant B cells in general and for 
PCNSL cells in particular. The clinical use of selinexor 
in lymphoma has been studied in a phase I trial studying 
patients diagnosed with relapsed/refractory NHL and a 
phase IIb study in patients with DLBCL [17], which has 
led to a recent approval by the FDA in such an adverse 
setting. Additionally, based on our pre-clinical experience, 
we recently used selinexor in a compassionate way for a 
patient diagnosed with DLBCL who developed an isolated 
CNS relapse after several lines of treatment. After a month 
of treatment a partial response was already observed while 
after 5 months of selinexor the patient remained asympto-
matic and the MRI (magnetic resonance imaging) showed 
a complete resolution of the brain tumors [19]. Ibrutinib 
Fig. 6  Treatment with selinexor and ibrutinib favors M1-like 
response in tumor-associated macrophages in CNS lymphoma PDXs. 
a Scheme representing mice treatment and monitoring. b Percent-
age of M1 and M2 TAMs by flow cytometry. Frequency of M2 
macrophages that express PD-1 (c), SIRPα (d) or co-express both 
markers (e). f Percentage of  CD20+ cells in the brains from mice. g 
Percentage of malignant cells  CD20+ expressing PD-L1 in the differ-
ent treatment groups. Percentage of malignant cells expressing CD47 
(h) and co-expressing PD-L1 and CD47 (i). (*P < 0.05, **P < 0.01, 
***P < 0.001, Mann–Whitney test. Graphs show mean ± SEM). CI 
combination index
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is also able to cross the BBB and is active against CNS 
lymphoma cells. In this setting, ibrutinib has been assayed 
alone [6, 7] or in combination with chemotherapy [5], 
showing high response rates but relatively short remis-
sions, while other BTK inhibitors have showed similar 
efficacy [39]. Based on all these data, herein we proposed 
to combine selinexor with ibrutinib in models of PCNSL.
Exploitation of the immune response to a neoplastic pro-
cess is currently a widespread strategy to treat cancer. To 
achieve this, different approaches are being pursued, spe-
cially focused on harnessing the anti-tumoral capacity of 
T lymphocytes via checkpoint inhibition [40]. Intriguingly, 
evading a T-cell mediated immune response seems to be a 
common feature of PCNSL since a high percentage of cases 
are affected by both MHC-I loss and/or PD-L1/2 amplifica-
tion [14], and the infiltration by T lymphocytes is scarce 
while present [9–12]. However, some immunotherapies have 
already shown to be effective in PCNSL, such as anti-CD20 
and, more recently, anti-PD-1 therapy, with both preclinical 
[41] and clinical evidences, although with only informa-
tion for four patients, where responses lasted a median of 
15 months [42]. In agreement, anti-PD-1 is highly effective 
in Hodgkin’s lymphoma [43] even though the expression of 
PD-1 on T-cells is heterogeneous and PD-L1/2 amplification 
and lack of MHC-I expression on tumoral cells are com-
mon, characteristics that should hamper a T-cell mediated 
response [44]. In this regard, a role for the innate immune 
system in the development of PCNSL is further supported 
by recent discovery of PD-1 expression in TAMs [28] and 
the fact that these immune cells have also been found to be 
suppressed by the MHC-I system in cancer cells, render-
ing malignant cells that downregulate MHC-I to avoid T 
cell surveillance exposed to macrophage phagocytosis [45]. 
Therefore, paralleling the few PCNSL patients treated with 
anti-PD-1 achieving a complete response, this effect may 
be related to a macrophage-mediated anti-tumoral effect 
after PD-1 pharmacological blockage. Supporting that, 
herein we describe the presence of brain PD-1-positive M2 
macrophages in two orthotopic mouse models of PCNSL, 
including PDXs. The recognition of human malignant cells 
by mice macrophages has been previously demonstrated in 
mice models of PCNSL [20, 46] and other tumoral mod-
els such as colon cancer [28], pancreatic adenocarcinoma 
[47] and T-cell lymphoma [48]. TAMs in CNLS have been 
found to be supportive of the tumoral growth and related to 
prognosis of patients [9, 13]. Also, indoleamine 2,3 dioxyge-
nase (IDO) and IL-10, which may be markers of macrophage 
infiltration, are related to prognosis or response to immu-
nomodulatory therapy [9, 13, 49]. The observed expression 
of PD-1 and SIRPα by innate immune cells responding to 
and interacting with CNS lymphoma cells in vivo indicates 
that their anti-tumoral effect is partially impaired but also 
opens the opportunity to potentially target these cells by 
immunotherapies that aim at potentiating the autologous 
anti-tumoral immune response. In this regard, it has been 
previously shown how immunomodulation by pomalidome 
in mouse models of PCNSL results in reprogramming of 
M2 macrophages into M1 [20]. In the clinical setting, both 
pomalidomide and lenalidomide are showing preliminary 
therapeutic activity in a phase I study in patients diagnosed 
with PCNSL (combined with dexamethasone) [29]. Also, 
lenalidomide in combination with rituximab showed signifi-
cant clinical activity in relapsed/refractory PCNSL patients 
[49, 50]. Combination therapies that not only directly attack 
the survival of malignant cells but also alter the immune 
function are therefore an interesting approach when aiming 
at achieving long lasting responses. In this regard, inhibit-
ing BTK can have this double effect in B-cell malignan-
cies, since BTK protein is not only involved in malignant 
B-cell survival but is also required for the tumor-promoting 
effect of macrophages [35, 36]. Taking this into account, 
we hypothesized that combining ibrutinib with selinexor 
would also be effective in harnessing the innate immune 
response mediated by TAMs in PCNSL. In fact, selinexor 
and ibrutinib combination treatment was able to not only 
increase mouse survival but to shift the innate immune 
response towards a more inflammatory phenotype, specifi-
cally defined by downregulation of PD-1 and SIRPα in M2 
macrophages and increased proportion of M1 macrophages 
as well as modulation of additional M1 and M2-like proper-
ties consistent with loss of pro-tumoral M2 characteristics. 
Confirmation of these results and additional studies in the 
interaction of malignant cells and the immune system in 
PCNSL using different in vivo models, including syngeneic 
mice, is needed to further confirm the potential clinical value 
of the combination of selinexor and ibrutinib in patients 
diagnosed with PCNSL.
Conclusions
Our results show that selinexor blocks tumor growth and 
prolongs survival in a bioluminescent mouse model, while 
its combination with ibrutinib further increases survival. 
Alongside this, treatment with this combination not only had 
a direct cytotoxic effect in malignant cells but also favored 
an anti-tumoral innate immune response by shifting polari-
zation of tumor-infiltrating macrophages toward inflamma-
tory M1 and diminishing PD-1 and SIRPα expression in the 
remaining tumor-promoting M2 macrophages, highlighting 
the pathogenic role of the innate immune microenvironment 
in PCNSL. Herein we provide pre-clinical evidence for the 
development of selinexor and ibrutinib as a new therapeu-
tic option with cytotoxic and immunomodulatory potential 
for patients diagnosed with PCNSL, aiming at a durable 
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response to improve the fatal prognosis of patients diagnosed 
with this disease.
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